ChitogenX Inc.
ChitogenX Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic soft tissue repair technologies to enhance the success rate of orthopaedic and sports medicine surgeries in Canada. It develops Ortho-R, a biopolymer for rotator cuff repair; and Ortho-M, a biopolymer for meniscus repair. The company was formerly known as Ortho Regene… Read more
ChitogenX Inc. (CHNXF) - Net Assets
Latest net assets as of October 2024: $-7.36 Million USD
Based on the latest financial reports, ChitogenX Inc. (CHNXF) has net assets worth $-7.36 Million USD as of October 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($385.00K) and total liabilities ($7.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-7.36 Million |
| % of Total Assets | -1912.73% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
ChitogenX Inc. - Net Assets Trend (2019–2024)
This chart illustrates how ChitogenX Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ChitogenX Inc. (2019–2024)
The table below shows the annual net assets of ChitogenX Inc. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-01-31 | $-6.18 Million | +37.23% |
| 2023-01-31 | $-9.84 Million | -38.56% |
| 2022-01-31 | $-7.10 Million | -294.45% |
| 2021-01-31 | $-1.80 Million | +24.93% |
| 2020-01-31 | $-2.40 Million | -307.25% |
| 2019-01-31 | $-589.07K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ChitogenX Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1931000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $20.53 Million | % |
| Total Equity | $-6.18 Million | 100.00% |
ChitogenX Inc. Competitors by Market Cap
The table below lists competitors of ChitogenX Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ODFJELL DRILL
MU:OD3
|
$91.47K |
|
Stark Focus Group Inc
PINK:SKFG
|
$91.48K |
|
Strats Trust US Cellular GIC
NYSE:GJH
|
$91.51K |
|
Alussa Energy Acquisition Corp. II
NYSE:ALUB-UN
|
$91.53K |
|
Karbon Capital Partners Corp. Class A Ordinary Shares
NASDAQ:KBON
|
$91.42K |
|
United Corporations Limited
TO:UNC
|
$91.41K |
|
VNET Group Inc
STU:217A
|
$91.41K |
|
Vivanco Gruppe AG
F:VG0K
|
$91.37K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ChitogenX Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -9,843,000 to -6,178,000, a change of 3,665,000.
- Net loss of 1,554,000 reduced equity.
- New share issuances of 937,000 increased equity.
- Other factors increased equity by 4,282,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.55 Million | -25.15% |
| Share Issuances | $937.00K | +15.17% |
| Other Changes | $4.28 Million | +69.31% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares ChitogenX Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-01-31 | $-0.02 | $0.01 | x |
| 2020-01-31 | $-0.10 | $0.01 | x |
| 2021-01-31 | $-0.05 | $0.01 | x |
| 2022-01-31 | $-0.20 | $0.01 | x |
| 2023-01-31 | $-0.19 | $0.01 | x |
| 2024-01-31 | $-0.07 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ChitogenX Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.34 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.25 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.59 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.21 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.25 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-936.20K |
Industry Comparison
This section compares ChitogenX Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ChitogenX Inc. (CHNXF) | $-7.36 Million | 0.00% | N/A | $91.44K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |